Home › Research › Biomarkers
Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
Jutten RJ, Sikkes SAM, Van der Flier WM, Scheltens P, Visser PJ, Tijms BM, Alzheimer's Disease Neuroimaging Initiative.. Neurology, 2021-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To investigate the influence of heterogeneity in disease progression for detecting treatment effects in Alzheimer disease (AD) trials, using a simulation study. Methods Individuals with an abnormal amyloid PET scan, diagnosis of mild cognitive impairment or dementia, baseline Mini-Mental State Examination (MMSE) score ≥24, global Clinical Dementia Rating (CDR) score of 0.5, and ≥1 follow-up cognitive assessment were selected from the Alzheimer's Disease Neuroimaging Initiative database (n = 302, age 73 ± 6.7; 44% female; 16.1 ± 2.7 years of education; 69% APOE ε4 carrier). We simulated a clinical trial by randomly assigning individuals to a "placebo" and "treatment" group and subsequently computed group differences on the CDR-sum of boxes (CDR-SB), Alzheimer's Disease Assessment Scale-cognitive subscale-13 and MMSE after 18 months follow-up. We repeated this simulation 10,000 times to determine the 95% range of effect sizes. We further studied the influence of known AD risk factors (age, sex, education, APOE ε4 status, CSF total tau levels) on the variability in effect sizes. Results Individual trajectories on all cognitive outcomes were highly variable, and the 95% ranges of possible effect sizes at 18 months were broad (e.g., ranging from 0.35 improvement to 0.35 decline on the CDR-SB). Results of recent anti-amyloid trials mostly fell within these 95% ranges of effect sizes. APOE ε4 carriers and individuals with abnormal baseline tau levels showed faster decline at group level, but also greater within-group variability, as illustrated by broader 95% effect size ranges (e.g., ±0.70 points for the CDR-SB). Conclusions Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression. We provide guidance for a priori effect sizes on cognitive outcomes for detecting true change, which is crucial for future AD trials.
What this study adds
Evidence grade: Low
The record lists 302 participants. This simulation study found that individual cognitive trajectories in early Alzheimer's disease are highly variable, producing wide ranges of possible effect sizes in trials. The results of recent anti-amyloid trials mostly fell within these ranges, meaning the study does not show that any treatment works.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jutten, R. J., Sikkes, S. A. M., Van der Flier, W. M., Scheltens, P., Visser, P. J., Tijms, B. M., et al. (2021). Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology. https://doi.org/10.1212/wnl.0000000000012022
Vancouver
Jutten RJ, Sikkes SAM, Van der Flier WM, Scheltens P, Visser PJ, Tijms BM, et al. Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology. 2021. doi:10.1212/wnl.0000000000012022. PMID: 34550903.
BibTeX
@article{jutten2021-34550903,
author = {Jutten, R. J. and Sikkes, S. A. M. and Van der Flier, W. M. and Scheltens, P. and Visser, P. J. and Tijms, B. M. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity}},
journal = {Neurology},
year = {2021},
doi = {10.1212/wnl.0000000000012022},
pmid = {34550903},
url = {https://doi.org/10.1212/wnl.0000000000012022}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Individual trajectories on all cognitive outcomes were highly variable, and the 95% ranges of possible effect sizes at 18 months were broad (e.g., ranging from 0.35 improvement to 0.35 decline on the CDR-SB).
- Results of recent anti-amyloid trials mostly fell within these 95% ranges of effect sizes.
- Conclusions Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression.
Why it matters
This simulation study found that individual cognitive trajectories in early Alzheimer's disease are highly variable, producing wide ranges of possible effect sizes in trials. The results of recent anti-amyloid trials mostly fell within these ranges, meaning the study does not show that any treatment works.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants302
- Evidence strengthLow
How this study scored 56/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 54 of the 96 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 302 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 82 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 11.7 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 4 / 6 | Cited 8.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 2 / 4 | Cited 44 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34550903) |
| Free to read | 2 / 2 | Free to read |
| Points | 54 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 54 of the 96 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000012022
- PubMed: 34550903
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also in Biomarkers
137 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.